HSBC raised the firm’s price target on Gilead (GILD) to $133 from $110 and keeps a Hold rating on the shares as part of a 2026 outlook for the pharma group. The firm believes the sector is well positioned to outperform in 2026, “even more so if AI panic kicks in.” HSBC’s preferred stocks are “growth bucket ideas,” but says “fallen angels and value could work as well.”
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD:
- Assembly Biosciences announces interim results from ABI-1179, ABI-5366 trials
- Mirum’s deal for Bluejay a positive readthrough to Vir, says Needham
- Gilead Sciences’ Strong Market Position and Promising Anito-cel Data Support Buy Rating
- Gilead’s Kite presents new analysis on second-line Yescarta therapy
- Arcellx announces new data for its iMMagine-1 study in patients with RRMM